Zoetis Expands Diagnostics Portfolio With VitalRADS Acquisition

Zoetis, the global animal health company spun out of Pfizer, has announced plans to acquire VitalRADS, a provider of veterinary imaging services. The deal signals a deliberate strategic push by Zoetis to broaden its diagnostics capabilities beyond its core pharmaceuticals and vaccines business, extending its reach into the fast-growing field of veterinary imaging.

Veterinary imaging — encompassing radiology reads, telemedicine consultations, and related diagnostic support — has become an increasingly valuable segment as pet owners demand higher standards of care and veterinary practices face pressure to deliver faster, more accurate diagnoses. By folding VitalRADS into its portfolio, Zoetis positions itself to offer a more integrated suite of tools to veterinary clinics and hospitals.

Read more Glucotrack and Lōkahi Therapeutics Close Merger to Form AI-Driven Public Biotech Platform →

The acquisition fits a broader pattern the company has pursued in recent years: using targeted deals to build out its diagnostics and data services arm alongside its legacy drug and vaccine lines. This kind of vertical integration — where a single company can supply both the treatment and the diagnostic pathway leading to it — tends to deepen client relationships and create stickier revenue streams that are less vulnerable to generic competition than traditional pharmaceuticals.

For the veterinary industry, the deal underscores how animal health is increasingly mirroring trends in human medicine, where large players have aggressively consolidated diagnostic and therapeutic capabilities under one roof. As companion animal spending continues to rise in the United States, the competitive pressure on independent diagnostic service providers is likely to intensify.

Financial terms of the transaction were not disclosed. Continue reading at SeekingAlpha.